ReviewACS omega2025
Nanoparticles in Antibacterial Therapy: A Systematic Review of Enhanced Efficacy against Intracellular Bacteria.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications.Scientific reports · 2026Article
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- Tannic Acid and Copper-Modified ZIF-8 Metal Organic Framework as a Cefotaxime Delivery System for Antimicrobial ActivityTurkish journal of pharmaceutical sciences · 2026Article
- Supramolecular strategy for compartment pathogen clearance and immuno-metabolic homeostasis to treat periodontitis.Nature communications · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- A Hemoglobin-Based Nanoparticle Delivery System Enhances the Pharmacokinetics and Efficacy of Tigecycline inBME frontiers · 2026Article
- Recombinant production of antimicrobial proteins in bacterial expression systems: Escherichia coli vs. lactic acid bacteria.Microbial cell factories · 2025Review
- Interaction of Nanoparticles with Multidrug-Resistant Bacteria.ACS omega · 2025Article
- Mechanism, Efficacy, and Safety of Natural Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Review
- Brucellosis in the omics era: integrative perspectives on Brucella genomic architecture, host-pathogen interactions, and disease dynamics.World journal of microbiology & biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracellular bacterial infections represent a considerable therapeutic challenge due to the ability of pathogens to invade and replicate within host cells, hampering the action of the immune system and the effectiveness of conventional antibiotics. Bacteria such as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.